TY - JOUR
T1 - Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome
T2 - An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines
AU - DeFilipp, Zachariah
AU - Ciurea, Stefan O.
AU - Cutler, Corey
AU - Robin, Marie
AU - Warlick, Erica D.
AU - Nakamura, Ryotaro
AU - Brunner, Andrew M.
AU - Dholaria, Bhagirathbhai
AU - Walker, Alison R.
AU - Kröger, Nicolaus
AU - Bejanyan, Nelli
AU - Atallah, Ehab
AU - Tamari, Roni
AU - Solh, Melhem M.
AU - Percival, Mary Elizabeth
AU - de Lima, Marcos
AU - Scott, Bart
AU - Oran, Betul
AU - Garcia-Manero, Guillermo
AU - Hamadani, Mehdi
AU - Carpenter, Paul
AU - DeZern, Amy E.
N1 - Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy
PY - 2023/2
Y1 - 2023/2
N2 - The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated in the context of the evidence. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of MDS experts comprising transplantation and nontransplantation physicians developed consensus treatment recommendations. This review summarizes the standard MDS indications for HCT and addresses areas of controversy. Recent prospective trials have confirmed that allogeneic HCT confers survival benefits in patients with advanced or high-risk MDS compared with nontransplantation approaches, and the use of HCT is increasing in older patients with good performance status. However, patients with high-risk cytogenetic or molecular mutations remain at high risk for relapse. It is unknown whether administration of novel therapies before or after transplantation may decrease the risk of disease relapse in selected populations. Ongoing and future studies will investigate revised approaches to disease risk stratification, patient selection, and post-transplantation approaches to optimize allogeneic HCT outcomes for patients with MDS.
AB - The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated in the context of the evidence. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of MDS experts comprising transplantation and nontransplantation physicians developed consensus treatment recommendations. This review summarizes the standard MDS indications for HCT and addresses areas of controversy. Recent prospective trials have confirmed that allogeneic HCT confers survival benefits in patients with advanced or high-risk MDS compared with nontransplantation approaches, and the use of HCT is increasing in older patients with good performance status. However, patients with high-risk cytogenetic or molecular mutations remain at high risk for relapse. It is unknown whether administration of novel therapies before or after transplantation may decrease the risk of disease relapse in selected populations. Ongoing and future studies will investigate revised approaches to disease risk stratification, patient selection, and post-transplantation approaches to optimize allogeneic HCT outcomes for patients with MDS.
KW - Allogeneic hematopoietic cell transplantation
KW - Evidence-based review
KW - Guideline
KW - Myelodysplastic syndrome
UR - http://www.scopus.com/inward/record.url?scp=85145302399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145302399&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2022.11.014
DO - 10.1016/j.jtct.2022.11.014
M3 - Article
C2 - 36436780
AN - SCOPUS:85145302399
SN - 2666-6367
VL - 29
SP - 71
EP - 81
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 2
ER -